Loading
Extracellular Vesicles in Disease / CAR-T Cell Therapy Research / CRISPR and Genetic Engineering · Journal article
Frontiers in Bioengineering and Biotechnology · August 17, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that examines engineering strategies for MSC-exosome-based CRISPR-Cas9 delivery platforms, focusing on cargo loading, targeting, and mechanistic rationale for treating immune-mediated diseases. It does not report original experimental results or clinical efficacy data, but rather synthesizes the state of knowledge and identifies obstacles to translation including manufacturing, safety, and regulatory challenges.
Narrative review. Immune-mediated diseases (target population for potential therapy; not studied in this review).
MSC-exosomes combined with CRISPR-Cas9 hold substantial therapeutic potential for immune-mediated diseases, although significant technical obstacles remain Key barriers to clinical translation include manufacturing scalability, safety concerns, and regulatory considerations Engineering focus areas include vehicle engineering, cargo packaging efficiency, biological barriers, and in vivo safety
Key barriers to clinical translation include manufacturing scalability, safety concerns, and regulatory considerations Engineering focus areas include vehicle engineering, cargo packaging efficiency, biological barriers, and in vivo safety
This review maps the landscape of a preclinical technology platform and identifies critical gaps before clinical translation. Clinicians and translational researchers should understand that MSC-exosome–CRISPR platforms remain in early development with unresolved manufacturing, safety, and regulatory questions.
This is a narrative review synthesizing mechanistic understanding and engineering strategies rather than reporting original experimental data or clinical outcomes, making it exploratory rather than evidence of efficacy.
As stated by the source record.
This review maps the landscape of a preclinical technology platform and identifies critical gaps before clinical translation. Clinicians and translational researchers should understand that MSC-exosome–CRISPR platforms remain in early development with unresolved manufacturing, safety, and regulatory questions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Mesenchymal stem cell-derived exosomes (MSC-Exos) combined with CRISPR-Cas9 hold substantial therapeutic potential for immune-mediated diseases, although significant technical obstacles remain. This review presents a comprehensive analysis of strategies for engineering MSC-Exos as delivery vehicles for CRISPR-Cas9, with emphasis on cargo-loading methodologies and surface modifications that enable targeting specific immune cell populations. We examine the mechanistic basis for the therapeutic effects of these engineered platforms and critically assess the challenges impeding clinical translation, including manufacturing scalability, safety concerns, and regulatory considerations. Key areas of focus for this Research Topic—vehicle engineering, cargo packaging efficiency, biological barriers, and in vivo safety—are systematically addressed. Finally, we discuss emerging directions, including next-generation gene editors and stimulus-responsive biomaterials. This review provides a balanced framework for advancing MSC-Exos-based nanoplatforms toward precision gene therapies for immune disorders.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.